Chandan Healthcare Ltd Q1 FY27 Earnings Analysis

- The company is undergoing rapid expansion with many new diagnostic centers and labs opened in FY26 and plans for continued growth in FY27. - They target opening 5 comprehensive centers and 20 standalone labs in FY27, covering all districts in Uttar Pradesh and Uttarakhand within two years before moving to other states. - Franchise network plans to scale aggressively from 130+ to 1,000 operational franchises over the next 24 months. - New initiatives like digital direct-to-consumer platforms, home sample collection, PET scans, and a genome lab are expected to drive growth. - Growth from government PPP projects in Punjab, Haryana, and Assam (worth INR 800 crores over 10 years) will begin contributing from Q2 FY27. - Overall revenue growth is expected to accelerate post expansion, with a top-line growth guidance and detailed forecasts to be provided after the first quarter results. - The company expects a balanced growth model, optimizing between expansion and profitability for sustained momentum.

- For FY27, growth is expected to improve significantly due to expansion efforts, particularly new diagnostic centers and labs started last financial year now contributing (Page 23). - Top-line growth is projected at around 20% in the current quarter, with better growth expected moving forward (Page 23). - EBITDA margin expected to be higher than FY26's 20.25%, with guidance after Q1 results (Page 23). - Expansion in 13+ states and focus on comprehensive diagnostic centers will drive revenue growth over next 3-4 years (Page 10). - EBITDA margins targeted at 32%-35% currently, aiming to maintain above 30% despite expansion costs (Page 7). - Longer-term EBITDA margins may reach around 40% after 2-3 years when expansion stabilizes (Page 10). - Revenue growth expected to be robust over 3-4 years, supported by PPP projects and franchisee growth (Page 10). - Profit after tax growing steadily, with FY26 PAT up 22.04% to INR 27.06 crores (Page 4).

- For FY27, Chandan Healthcare plans capital investment of INR 45-50 crores. - This includes setting up 20 standalone labs (each costing ~INR 1 crore) and 5 comprehensive centers (each costing INR 6-7 crores). - Comprehensive centers include pathology and full radiology services; standalone labs focus mainly on lab services. - Funding for this capex will come from internal accruals and proceeds from warrants floated for INR 104 crores (25% already received). - Expansion is focused on covering Uttar Pradesh and Uttarakhand districts in the next two years, with plans to proceed to other states afterward. - Company is also entering government PPP projects in Punjab, Haryana, and Assam, with capital expenditure in machines and infrastructure underway. - Expansion aims for balanced growth maintaining profitability and building a comprehensive nationwide diagnostic network.

- No plans for additional equity fundraising as per Amar Singh’s statement. - The company has already issued warrants worth INR 104 crores for fundraising. - 25% of the warrant amount has been received; remaining 75% expected within the next year. - Funds from warrants along with internal accruals will be used for expansion. - No mention of new debt fundraising; expansion capital largely covered by warrants and internal accruals.

- The company has secured projects under the PPP model in Punjab, Haryana, and Assam with a combined estimated project value of INR 800 crores over 10 years. - These projects were awarded in the last quarter and are currently under construction with machines being installed. - The projects are expected to start gradually from Q2 of the financial year 2026-27, with all machines expected to be operational within the year. - The management indicated that the revenue from these projects and other expansions will significantly boost the company's performance going forward.